Medexus Pharmaceuticals Inc. (MEDXF)
OTCMKTS · Delayed Price · Currency is USD
1.960
-0.080 (-3.92%)
Feb 12, 2026, 11:18 AM EST
Medexus Pharmaceuticals Revenue
Medexus Pharmaceuticals had revenue of $25.32M in the quarter ending December 31, 2025, a decrease of -15.56%. This brings the company's revenue in the last twelve months to $99.43M, down -9.23% year-over-year. In the fiscal year ending March 31, 2025, Medexus Pharmaceuticals had annual revenue of $108.33M, down -4.18%.
Revenue (ttm)
99.43M
Revenue Growth
-9.23%
P/S Ratio
0.67
Revenue / Employee
1.09M
Employees
91
Market Cap
66.79M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 108.33M | -4.72M | -4.18% |
| Mar 31, 2024 | 113.05M | 4.96M | 4.59% |
| Mar 31, 2023 | 108.10M | 31.40M | 40.93% |
| Mar 31, 2022 | 76.70M | -2.96M | -3.71% |
| Mar 31, 2021 | 79.66M | 24.15M | 43.52% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sofgen Pharma | 423.75M |
| The Cannabist Company Holdings | 349.84M |
| Jushi Holdings | 260.43M |
| MariMed | 157.38M |
| Earth Science Tech | 33.84M |
| Radnostix | 14.07M |
| Healthy Extracts | 3.59M |
| Growth Stalk Holdings | 583.34K |
Medexus Pharmaceuticals News
- 21 hours ago - Medexus Announces Fiscal Q3 2026 Results, Driven by Continued Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 8 days ago - Medexus Schedules Third Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 3 months ago - Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares - Newsfile Corp
- 3 months ago - Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares - Newsfile Corp
- 3 months ago - Medexus Pharmaceuticals Inc. (MDP:CA) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection - Newsfile Corp
- 3 months ago - Medexus Schedules Second Fiscal Quarter 2026 Conference Call - Newsfile Corp
- 4 months ago - Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors - Newsfile Corp